Skip to content
MARKETS / NASDAQ / OGI
NASDAQ · PHARMACEUTICAL PREPARATIONS

Organigram Global Inc. OGI

6 fiscal years on record · CAD · FY2024 reported · SEC filings only
CAD 159.8M
CAD -45.4M
CAD -859,000
In brief

What this company does

The Company cultivates, processes and sells cannabis and cannabis-derived products to consumers in Canada. As of September 30, 2025, it employed approximately 1,139 employees. The Company operates primarily in Canada, with partnerships in foreign jurisdictions including the United States, Germany, the United Kingdom and Australia. It acquired a manufacturing facility in Winnipeg, Manitoba, in 2021 as part of the acquisition of EIC. As a result of the acquisition of Motif in December 2024, it operates cannabis processing facilities in Aylmer, Ontario and London, Ontario. BAT made a strategic investment of approximately $221 million in the Company in connection with a March 2021 product development agreement between the two companies. Its Moncton Campus is a 536,000 square-foot facility with the capacity to produce more than 100,000 kg of dried cannabis flower annually.

Written from the business description in ORGANIGRAM GLOBAL INC.'s annual report to the U.S. Securities and Exchange Commission, filed 16 December 2025. Every sentence was checked against that document before publication.

Growth
CAD 159.8M
Revenue, FY2024 · full 6-year series below
Revenue CAD M Net income CAD M
FY2024 · Revenue 159.8 · Net income -45.4
80M-50M-100M201820192020202120222024
Compound annual growth
+26.4%
+14.7%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +14.7% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−28 cents
lost on every revenue dollar
Operating margin Net margin
FY2024 · Operating -22.3% · Net -28.4%
100%200%-50%-100%-150%201820192020202120222024
ROE

Not available in our data for this period.

Cash & shareholders
returned in FY2024 · dividends + net buybacks
Free cash flow CAD M
FY2024 · FCF -0.9
-50M-100M201820192020202120222024

Total assetsCAD 407.9M
Gross debtCAD 25,000.00
Current ratio4.92×

Not available: we don't have the cash figure for this period.

The 6-year record
6 fiscal years
Every figure from documents filed with the SEC · CAD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative
Metric 202420222021202020192018
Revenue CAD B0.20.10.10.10.10.0
Operating income CAD B−0.0−0.0−0.1−0.10.00.0
EBITDA CAD B−0.0−0.0−0.1−0.10.00.0
Income tax CAD B0.0−0.00.0−0.00.00.0
Net income CAD B−0.0−0.0−0.1−0.1−0.00.0
Free cash flow CAD B−0.0−0.1−0.0−0.1−0.1−0.1
EPS, diluted CAD −0.48−0.18−0.51−0.79−0.070.16
Dividend / sh CAD ······
Payout %······
ROE %······
Shares out B0.110.080.070.190.160.13

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Compare

This company against its peers

Provenance
Company facts, as filed
How we verify · 0 failures · 5 divergences in 29 reconciliationsAUDITED

Reconciled in 1 of 19 fiscal years. 5 of those reconciliations are divergences — the figures exist but don't fit the formula this check expects; that isn't the same as an error. 66 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures5 divergent
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inoutside the United States — SEC code Z4
Fiscal year endsSeptember 30
SEC categoryemerging growth company
Data on record since2018

Share this section

Download image